“…New kinase inhibitors are often developed by a multifaceted approach, including high‐throughput screening of compound libraries using biochemical/cellular assays or analogue synthesis. During our decade‐long research on kinase inhibitors, we have ascertained the importance of the heterocyclic core One less explored scaffold, imidazo[1,2‐ c ]pyrimidine, was previously investigated randomly for biological activities, such as antimicrobial, antimycobacterial, antitubercular, inotropic, antiinflammatory, analgesic, antipyretic, and ulcerogenic . Importantly, certain 5,7,8‐ and 2,5,8‐trisubstituted imidazo[1,2‐ c ]pyrimidine derivatives were described as potent Syk and Chk1 protein kinase inhibitors, respectively .…”